Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
Pharmabiz

DTAB recommends amendment of PSUR reporting period norms under NDCT Rules

DTAB recommends amendment of PSUR reporting period norms under NDCT Rules: Gireesh Babu, New Delhi Tuesday, April 7, 2026, 08:00 Hrs [IST] The Drugs Technical Advisory Board (DTAB ...

Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript

Cue Biopharma, Inc. ( CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Lucinda Warren - Interim CEO, Interim President,Principal ...

ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead ...

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by th ...
Morning Overview on MSN

Study details how brown recluse venom strips key molecules off cells

A new study has captured atomic-resolution snapshots of a brown recluse spider toxin latched onto cell-membrane lipids, ...